aTyr Pharma, Inc.
ATYR
$3.28
$0.185.81%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -33.43% | -97.81% | -94.34% | -94.34% | -96.60% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -33.43% | -97.81% | -94.34% | -94.34% | -96.60% |
| Cost of Revenue | 28.56% | 23.51% | 14.58% | 6.90% | -1.20% |
| Gross Profit | -29.08% | -62.16% | -48.24% | -38.85% | -29.36% |
| SG&A Expenses | 6.15% | 1.42% | -10.40% | -5.97% | -7.17% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 23.30% | 18.45% | 8.49% | 3.77% | -2.67% |
| Operating Income | -23.66% | -45.07% | -30.84% | -25.54% | -18.35% |
| Income Before Tax | -27.04% | -47.86% | -28.48% | -19.47% | -11.15% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -27.04% | -47.86% | -28.48% | -19.47% | -11.15% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -112.50% | -111.11% | -112.50% | -40.00% | 60.00% |
| Net Income | -27.06% | -47.89% | -28.51% | -19.48% | -11.14% |
| EBIT | -23.66% | -45.07% | -30.84% | -25.54% | -18.35% |
| EBITDA | -23.71% | -44.97% | -30.26% | -24.68% | -17.66% |
| EPS Basic | 8.94% | 2.73% | 26.38% | 37.64% | 40.38% |
| Normalized Basic EPS | 8.94% | 2.72% | 26.38% | 37.64% | 40.37% |
| EPS Diluted | 8.94% | 2.73% | 26.38% | 37.64% | 40.38% |
| Normalized Diluted EPS | 8.94% | 2.72% | 26.38% | 37.64% | 40.37% |
| Average Basic Shares Outstanding | 38.61% | 48.57% | 65.04% | 86.61% | 88.44% |
| Average Diluted Shares Outstanding | 38.61% | 48.57% | 65.04% | 86.61% | 88.44% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |